Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 6Lymphoma 6Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Carcinoma, Ovarian Epithelial 3Waldenstrom Macroglobulinemia 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Fallopian Tube Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

Gemcitabine 679130-nm albumin-bound paclitaxel 198Fluorouracil 186Oxaliplatin 175Albumin-Bound Paclitaxel 151Capecitabine 137Leucovorin 131Irinotecan 113Radiotherapy 95Taxes 83pembrolizumab 80Cisplatin 72Erlotinib Hydrochloride 69Radiosurgery 67Nivolumab 56Bevacizumab 54Drug Therapy 52Cyclophosphamide 49Magnetic Resonance Spectroscopy 46folfirinox 42Docetaxel 41Cetuximab 40Specimen Handling 37irinotecan sucrosofate 36S 1 (combination) 36Biopsy 31Radiation 29Paclitaxel 29Ipilimumab 27durvalumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Pancreatic Neoplasms × 7-hydroxystaurosporine × Clear all
NCT00031681 2013-09-30

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

National Cancer Institute (NCI)

Phase 1 Completed
41 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00045747 2013-06-24

UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Gastrointestinal

Pancreatic Neoplasms

NCT00039403 2013-01-23

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡